dm+d

83085007

New Medicines

Pruritus due to prurigo nodularis

Information

New formulation - repurposed medicine
Trevi Therapeutics
Trevi Therapeutics

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Modified-release formulation of an opioid, kappa receptor agonist, mu receptor antagonist
Prurigo nodularis is a chronic dermatologic condition characterised by severely pruritic skin nodules that are independent of underlying aetiology [1].
Pruritus due to prurigo nodularis
Oral